Top segments and regional performance

Last year, the company generated ‪24.25 B‬ HKD, the most of which — ‪17.23 B‬ HKD — came from its top-performing segment, Biologics, compared to ‪15.97 B‬ HKD the previous year. The greatest contribution came from North America, which accounted for ‪13.72 B‬ HKD last year, with ‪11.60 B‬ HKD the year before.